Rytelo
Payments companies reported to CMS as associated with Rytelo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rytelo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rytelo
These are the largest totals companies reported as associated with Rytelo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| James Mccloskey | Hackensack, NJ | Medical Oncology | $76,465.53 |
| Amit Mehta | Cary, NC | Hematology & Oncology | $60,886.38 |
| Jamie Koprivnikar | Hackensack, NJ | Medical Oncology | $58,647.07 |
| Moshe Levy | Dallas, TX | Medical Oncology | $46,885.72 |
| Robert Spiegel | Westfield, NJ | Hematology & Oncology | $34,050.77 |
| Bart Scott | Seattle, WA | Medical Oncology | $32,231.10 |
| Jessica Slaba | Sioux Falls, SD | Nurse Practitioner | $30,601.77 |
| Suresh Kumar Balasubramanian | Cleveland, OH | Internal Medicine | $29,188.49 |
| Solly Chedid | Pascagoula, MS | Hematology & Oncology | $26,790.36 |
| Muthu Kumaran | Little Rock, AR | Medical Oncology | $22,138.49 |
Prescribed Rytelo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.